Lantern Pharma (NASDAQ: LTRN), a clinical-stage precision oncology company leveraging artificial intelligence and machine learning, announced the closing of its registered direct offering, raising approximately $4.4 million in gross proceeds. The offering involved the sale of 2,135,923 shares of common stock, or pre-funded warrants in lieu thereof, at a price of $2.06 per share. In a concurrent private placement, the company issued unregistered warrants to purchase up to 2,135,923 additional shares at an exercise price of $2.27 per share. If fully exercised, these warrants could generate up to approximately $4.85 million in additional gross proceeds.
The capital raise is a strategic move to support Lantern's ongoing clinical programs and its proprietary RADR platform, which uses AI to match cancer patients with the most effective therapies. Lantern's clinical pipeline includes LP-184, an acylfulvene targeting solid tumors; LP-284, a TC-NER targeting compound for hematologic and solid tumors; and LP-300, a cisplatin/ethacraplatin analog being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma. Additionally, LP-184 is being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.
Importantly, Lantern's Zeta.ai platform, a multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the company. This development could enhance Lantern's financial sustainability and reduce reliance on capital markets. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
For investors, this offering provides liquidity to advance Lantern's pipeline and commercialize its AI capabilities. The warrants offer potential upside if the stock price appreciates above the exercise price. However, the dilutive effect of the new shares may weigh on existing shareholders. The news highlights Lantern's dual focus on drug development and AI-driven drug discovery, positioning it in the growing field of precision oncology. For the full press release, visit https://ibn.fm/Oh6jI.
